Piramal Pharma posts FY26 consolidated loss; reappoints directors

Revenue DeclinePat NegativeExceptional ItemResults View source PDF

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.7%1-day move

₹164.85

prior close

₹163.25

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.7+1.1+1.8+2.7-1.7-2.6-3.0+0.1+11.4+11.6+7.2+4.9+1.0—

Up moveDown movePending

AI summary

Piramal Pharma reported FY26 consolidated net loss of Rs 325.94 cr vs Rs 91.13 cr profit YoY, on revenue of Rs 8,869 cr (down from Rs 9,151 cr). Standalone PAT was Rs 700 cr (flat) on revenue of Rs 4,782 cr. Exceptional items of Rs 196 cr (consolidated) covered intangible impairment and Labour Code impact. Auditors gave an unmodified opinion. Board reappointed Chairperson Nandini Piramal, Peter DeYoung, and two independent directors, and named a new Company Secretary.

Likely market impact

Revenue and profits declined; consolidated loss raises concerns despite flat standalone PAT and clean audit opinion.